Trial reportIntegrative cancer therapies
Evaluating the Test-Retest Reliability and Measurement Error of a Sit-Stand-Power Test in Individuals Treated for Cancer.
Trial report in Integrative cancer therapies. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06039488 (The Impact of an 8-week Exercise Program on Physical Function in Individuals With Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Impact of an 8-week Exercise Program on Physical Function in Individuals With Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionMuscular strength and physical function are commonly assessed in exercise oncology trials, yet muscular power is often overlooked despite being an important determinant of morbidity and mortality. The sit-to-stand power (STSp) test offers a rapid, low-cost method to evaluate lower-body power. The purpose of this study was to assess the test-retest reliability, measurement error, and minimal detectable change (MDC) of the STSp test assessed using a linear power transducer in individuals treated for cancer.
methodsAdults with a history of cancer completed the STSp test on 2 occasions (2 -10 days apart), to evaluate test-retest reliability using intraclass correlation coefficients (ICC(3,1)). Standard error of measurement (SEM) and MDC were calculated.
resultsOne hundred and three individuals treated for cancer (88.3% female; mean age = 60.2 ± 10.4 years) completed the test-retest assessment. The sample was racially diverse, with 51% identifying as White and 41% as Black. Breast cancer was the most common diagnosis (68.9%). Disease stage was primary early stage, with 45.6% classified as stage I and 22.3% stage II. Participants had undergone surgery (95.2%), radiation (63.1%), and chemotherapy (60.2%). The STSp test demonstrated good reliability for peak power (ICC = 0.86; 95% CI: 0.80-0.91) and average power (ICC = 0.86; 95% CI: 0.79-0.90). The peak power SEM and MDC were 199.9 W and 554.10 W, respectively. The average power SEM and MDC were 179.05 W and 496.30 W, respectively.
conclusionThe STSp test demonstrated good test-retest reliability for assessing lower-body muscular power in individuals treated for cancer. Given its low cost and feasibility, the STSp test may be useful for clinicians seeking to monitor changes in lower extremity power in oncological settings. However, the relatively large SEM and MDC values indicate substantial within-subject variability, underscoring the need for further protocol standardization. CLINICAL
trial registrationClinicalTrials.gov, NCT06039488.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.